Mesa Laboratories (MLAB) SVP Operations David Sells 2,454 Shares

On June 15, 2026, Brian Archbold, the Senior Vice President of Operations at MLAB, sold 2,454 shares of the company. This insider transaction is part of a series of trades disclosed by MLAB executives, including other transactions by John Sakys, the CFO.

Insider Buying and Selling at Mesa Laboratories, Inc.

Insider activity at MLAB on June 15, 2026, was notable. Brian Archbold, SVP Operations, sold a total of 2,454 shares, while CFO John Sakys was active with multiple transactions. Sakys bought 2,717 shares at $104.08 and made several other trades on the same day.

Other Institutional Activity in MLAB

There's been significant institutional movement in MLAB. Long Path Partners LP increased its stake by 178,360 shares, now holding 405,583 shares valued at about $35.9 million. BlackRock, Inc. reduced its position by 4,815 shares, ending with 393,851 shares worth approximately $34.8 million. Boston Partners added 55,335 shares to hold 268,711 shares valued at $23.8 million. Select Equity Group, L.P. also increased its holdings by 29,450 shares, closing with 235,885 shares valued at $20.9 million.

Mesa Laboratories, Inc. Stock Down 17.7%

MLAB shares are trading around $104.08. Although specific financial metrics like market cap and P/E ratio are not available, the stock's activity suggests robust trading interest. The peer activity indicates varied institutional confidence in the stock's performance.

Analysts Set New Price Targets

Analysts have been actively updating their views on MLAB. On February 4, 2026, Wells Fargo maintained a 'hold' rating with a price target of $94. Evercore ISI previously maintained a 'buy' rating with a target of $106. The consensus among analysts remains mixed, reflecting differing outlooks on MLAB's future performance.

Bottom Line

Insider sales, like those by Brian Archbold, provide insight into executive sentiment at MLAB. Institutional investors show varied confidence levels, with some increasing and others reducing their stakes. Analyst ratings suggest a cautious outlook, with mixed recommendations from key firms. As always, these insights reflect past actions and may not indicate current positions or future performance.